JP7493454B2 - Ｂｃｌ６阻害剤 - Google Patents

Ｂｃｌ６阻害剤 Download PDF

Info

Publication number
JP7493454B2
JP7493454B2 JP2020555420A JP2020555420A JP7493454B2 JP 7493454 B2 JP7493454 B2 JP 7493454B2 JP 2020555420 A JP2020555420 A JP 2020555420A JP 2020555420 A JP2020555420 A JP 2020555420A JP 7493454 B2 JP7493454 B2 JP 7493454B2
Authority
JP
Japan
Prior art keywords
amino
chloro
oxazepino
quinolin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521165A5 (2
JP2021521165A (ja
Inventor
ベンジャミン・リチャード・ベレニー
クワイ・ミン・ジャック・チュン
オーウェン・アレクサンダー・デイビス
スウェン・ヘルダー
ローズマリー・ハックベイル
ギャビン・コリー
ミルコ・メニコーニ
アルフィー・ブレナン
マシュー・ガース・ロイド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Cancer Research Technology Ltd
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1806132.5A external-priority patent/GB201806132D0/en
Priority claimed from GBGB1819136.1A external-priority patent/GB201819136D0/en
Application filed by Institute of Cancer Research Royal Cancer Hospital, Cancer Research Technology Ltd filed Critical Institute of Cancer Research Royal Cancer Hospital
Publication of JP2021521165A publication Critical patent/JP2021521165A/ja
Publication of JP2021521165A5 publication Critical patent/JP2021521165A5/ja
Priority to JP2024082277A priority Critical patent/JP7855637B2/ja
Application granted granted Critical
Publication of JP7493454B2 publication Critical patent/JP7493454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020555420A 2018-04-13 2019-04-12 Ｂｃｌ６阻害剤 Active JP7493454B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024082277A JP7855637B2 (ja) 2018-04-13 2024-05-21 Ｂｃｌ６阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1806132.5 2018-04-13
GBGB1806132.5A GB201806132D0 (en) 2018-04-13 2018-04-13 Inhibitor coumpounds
GB1819136.1 2018-11-23
GBGB1819136.1A GB201819136D0 (en) 2018-11-23 2018-11-23 Inhibitor compounds
PCT/GB2019/051058 WO2019197842A1 (en) 2018-04-13 2019-04-12 Bcl6 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024082277A Division JP7855637B2 (ja) 2018-04-13 2024-05-21 Ｂｃｌ６阻害剤

Publications (3)

Publication Number Publication Date
JP2021521165A JP2021521165A (ja) 2021-08-26
JP2021521165A5 JP2021521165A5 (2) 2022-02-07
JP7493454B2 true JP7493454B2 (ja) 2024-05-31

Family

ID=66240166

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555420A Active JP7493454B2 (ja) 2018-04-13 2019-04-12 Ｂｃｌ６阻害剤

Country Status (16)

Country Link
US (3) US11512095B2 (2)
EP (3) EP4201939B1 (2)
JP (1) JP7493454B2 (2)
KR (2) KR20250105504A (2)
CN (2) CN119330979A (2)
AU (2) AU2019253510B2 (2)
BR (1) BR112020020832A2 (2)
CA (1) CA3095371A1 (2)
DK (1) DK3774817T3 (2)
ES (2) ES2939776T3 (2)
HR (1) HRP20230120T1 (2)
IL (2) IL296734B2 (2)
MX (2) MX2020010805A (2)
PT (1) PT3774817T (2)
SG (1) SG11202009735QA (2)
WO (1) WO2019197842A1 (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095371A1 (en) 2018-04-13 2019-10-17 Cancer Research Technology Limited Bcl6 inhibitors
GB201909573D0 (en) 2019-07-03 2019-08-14 Cancer Research Tech Ltd Modulation of T cell cytotoxicity and related therapy
GB201914860D0 (en) * 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
CA3154386A1 (en) * 2019-10-17 2021-04-22 Michael Berlin Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
KR20230171979A (ko) 2021-04-16 2023-12-21 아비나스 오퍼레이션스, 인코포레이티드 Bcl6 단백질 분해의 조절제 및 관련 사용 방법
PE20250756A1 (es) 2022-06-06 2025-03-13 Treeline Biosciences Inc Degradadores bifuncionales de bcl6 de quinolona triciclica
EP4536649A1 (en) 2022-06-13 2025-04-16 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
KR20250023481A (ko) 2022-06-13 2025-02-18 트리라인 바이오사이언시스, 인크. 1,8-나프티리딘-2-온 이종이작용성 bcl6 분해제
CN119497710A (zh) * 2022-07-19 2025-02-21 丹娜-法伯癌症研究院 喹喔啉二酮和吡啶并[2,3-b]吡嗪-2,3-二酮b细胞淋巴瘤6(bcl6)降解剂及其用途
WO2024193464A1 (zh) * 2023-03-17 2024-09-26 西藏海思科制药有限公司 一种含氮三并环衍生物及其在医药上的应用
AU2024331309A1 (en) * 2023-09-01 2026-03-19 Treeline Biosciences, Inc. Tricyclic quinolone bcl6 bifunctional degraders
AU2024331602A1 (en) * 2023-09-01 2026-03-19 Treeline Biosciences, Inc. Bcl6 bifunctional degraders
CN120987969A (zh) * 2024-05-21 2025-11-21 中国药科大学 一类蛋白靶向降解嵌合体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508273A (ja) 2008-11-11 2012-04-05 ジェ イル ファーマシューティカル カンパニー リミテッド 新規なトリサイクリック誘導体またはその薬学的に許容可能な塩、それらの製造方法およびそれらを含む薬学的組成物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0259572A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ベンズイミダゾロン誘導体又はその塩類
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CA2349616A1 (en) 1998-12-04 2000-06-15 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
IL147309A0 (en) 1999-07-21 2002-08-14 Fujisawa Pharmaceutical Co Benzimidazolone derivatives and pharmaceutical compositions containg the same
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
WO2008066887A2 (en) 2006-11-30 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of bcl6
US8686008B2 (en) 2007-08-16 2014-04-01 The University Of Mississippi Highly selective sigma receptor ligands
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
SG187502A1 (en) 2008-02-01 2013-02-28 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
BRPI1006942A2 (pt) 2009-01-23 2016-04-12 Rigel Pharmaceuticals Inc composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto
KR20120114355A (ko) 2010-01-13 2012-10-16 글락소스미스클라인 엘엘씨 화합물 및 방법
CA2840883C (en) 2011-07-07 2019-07-16 Merck Patent Gmbh Substituted azaheterocycles
CA2877146C (en) 2012-06-18 2020-10-20 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
EP2964642B1 (en) 2013-03-05 2017-11-15 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
US9943506B2 (en) 2013-06-17 2018-04-17 Cornell University BCL6 inhibitors as anticancer agents
CN105017159B (zh) 2014-04-28 2019-05-17 四川大学 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途
US10266549B2 (en) 2014-08-25 2019-04-23 Salk Institute For Biological Studies ULK1 inhibitors and methods using same
US20160060260A1 (en) 2014-08-29 2016-03-03 Board Of Regents, The University Of Texas System Bromodomain inhibitors for treating disease
HK1244427A1 (zh) 2014-12-06 2018-08-10 Intra-Cellular Therapies, Inc. 有机化合物
WO2017007658A1 (en) 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
US11001570B2 (en) 2016-12-13 2021-05-11 Boehringer Ingelheim International Gmbh 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors
US11161839B2 (en) 2017-05-26 2021-11-02 The Institute Of Cancer Research: Royal Cancer Hospital 2-quinolone derived inhibitors of BCL6
JP7202315B2 (ja) 2017-05-26 2023-01-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
CA3095371A1 (en) 2018-04-13 2019-10-17 Cancer Research Technology Limited Bcl6 inhibitors
GB201819136D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508273A (ja) 2008-11-11 2012-04-05 ジェ イル ファーマシューティカル カンパニー リミテッド 新規なトリサイクリック誘導体またはその薬学的に許容可能な塩、それらの製造方法およびそれらを含む薬学的組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cell Reports，2017年，Vol. 20，pp. 2860-2875

Also Published As

Publication number Publication date
MX2023004920A (es) 2023-05-16
CA3095371A1 (en) 2019-10-17
EP4201939A1 (en) 2023-06-28
BR112020020832A2 (pt) 2021-01-19
ES3060268T3 (en) 2026-03-25
HRP20230120T1 (hr) 2023-06-09
EP4201939C0 (en) 2025-12-31
CN119330979A (zh) 2025-01-21
EP3774817A1 (en) 2021-02-17
EP3774817B1 (en) 2022-12-07
PT3774817T (pt) 2023-03-09
KR20250105504A (ko) 2025-07-08
CN112334475A (zh) 2021-02-05
AU2023263501A1 (en) 2023-11-30
US20210163497A1 (en) 2021-06-03
IL277778A (en) 2020-11-30
ES2939776T3 (es) 2023-04-26
AU2019253510B2 (en) 2023-08-10
AU2023263501B2 (en) 2026-01-08
CN112334475B (zh) 2024-10-29
US20260042776A1 (en) 2026-02-12
IL296734B2 (en) 2025-06-01
IL277778B (en) 2022-11-01
US20230287003A1 (en) 2023-09-14
DK3774817T3 (da) 2023-02-13
US11512095B2 (en) 2022-11-29
WO2019197842A1 (en) 2019-10-17
IL277778B2 (en) 2023-03-01
JP2024119835A (ja) 2024-09-03
KR20200144109A (ko) 2020-12-28
US12486285B2 (en) 2025-12-02
KR102830237B1 (ko) 2025-07-07
JP2021521165A (ja) 2021-08-26
IL296734A (en) 2022-11-01
EP4729127A2 (en) 2026-04-22
SG11202009735QA (en) 2020-10-29
EP4201939B1 (en) 2025-12-31
AU2019253510A1 (en) 2020-10-22
IL296734B1 (en) 2025-02-01
MX2020010805A (es) 2021-01-29

Similar Documents

Publication Publication Date Title
JP7493454B2 (ja) Ｂｃｌ６阻害剤
US11161839B2 (en) 2-quinolone derived inhibitors of BCL6
EP3630291A1 (en) Benzimidazolone derived inhibitors of bcl6
RU2693460C2 (ru) ПРОИЗВОДНЫЕ N2-(2-ФЕНИЛ)-ПИРИДО[3,4-d]ПИРИМИДИН-2,8-ДИАМИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ MPS1 ИНГИБИТОРА
HK40095873A (en) Bcl6 inhibitors
HK40046058A (en) Bcl6 inhibitors
HK40046058B (en) Bcl6 inhibitors
EA050300B1 (ru) Ингибиторы bcl6
HK40111483A (en) 2-quinolone derived inhibitors of bcl6
HK40111504A (en) Benzimidazolone derived inhibitors of bcl6
HK40025715A (en) Benzimidazolone derived inhibitors of bcl6

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240521

R150 Certificate of patent or registration of utility model

Ref document number: 7493454

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150